$2.92
-0.05 (-1.68%)
Open$2.96
Previous Close$2.97
Day High$3.01
Day Low$2.92
52W High$4.00
52W Low$1.51
Volume—
Avg Volume251.3K
Market Cap291.07M
P/E Ratio—
EPS$-0.70
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+714.4% upside
Current
$2.92
$2.92
Target
$23.78
$23.78
$21.93
$23.78 avg
$37.21
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.54M | 3.64M | 119.79M |
| Net Income | -69,697,889 | -64,588,241 | 199.8K |
| Profit Margin | -1,971.7% | -1,873.1% | 0.2% |
| EBITDA | -66,109,324 | -64,666,245 | 316.5K |
| Free Cash Flow | — | — | 248.3K |
| Rev Growth | -2.9% | -2.9% | -0.9% |
| Debt/Equity | 0.10 | 0.10 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |